Description

Endjerix-V (HBsAg) Vaccine for Adults – 1 ml, 20 mcg, 10 vial

Composition

Active Ingredient: HBsAg (Hepatitis B surface antigen) at a concentration of 20 mcg per 1 ml.

Mechanism of Action

Endjerix-V works by stimulating the immune system to produce antibodies against the Hepatitis B virus, providing active immunity against infection.

Pharmacological Properties

The vaccine contains HBsAg, which triggers the body’s immune response to develop antibodies specific to the surface antigen of the Hepatitis B virus, thereby conferring protection against infection.

Indications for Use

Endjerix-V is indicated for:

• Prevention of Hepatitis B virus infection in adults.

Contraindications

Avoid use in individuals with:

• Known hypersensitivity to any component of the vaccine.
• History of a severe allergic reaction to a previous dose.

Side Effects

Common side effects may include injection site reactions, mild fever, fatigue, and muscle aches. Serious allergic reactions are rare but possible.

Usage Instructions

Administration: Administer Endjerix-V via intramuscular injection. Ensure proper shaking of the vial before use. Dosage and vaccination schedule should be determined by a healthcare professional based on individual risk factors.

Benefits Compared to Analogues

Endjerix-V has demonstrated high efficacy in preventing Hepatitis B infection, with clinical trials showing a strong immune response and long-term protection. Compared to other Hepatitis B vaccines, Endjerix-V offers reliable and durable immunity against the virus.

Suitable Patient Groups

Endjerix-V is suitable for adults seeking protection against Hepatitis B. Consult a healthcare provider for vaccination recommendations tailored to specific patient groups, including children and the elderly.

Storage and Shelf Life

Store Endjerix-V as per the manufacturer’s instructions. Ensure proper refrigeration to maintain vaccine potency. Check the expiration date on the packaging and do not use expired doses.

Packaging Description

Endjerix-V is available in vials containing 1 ml of the vaccine solution, each vial providing a dosage of 20 mcg of HBsAg. Each package contains 10 vials for multiple doses.

Clinical Evidence and Proven Effectiveness

Endjerix-V (HBsAg) has been extensively researched and proven effective in preventing Hepatitis B infection. Studies have shown high rates of seroprotection post-vaccination, indicating robust immunity against the virus.

Published research in the Journal of Infectious Diseases has highlighted the long-term efficacy of HBsAg vaccines in reducing Hepatitis B incidence, particularly in high-risk populations like healthcare workers and individuals with liver disease.

Additional Information

Completing the full vaccination schedule with Endjerix-V is crucial for optimal protection against Hepatitis B. Any adverse reactions or concerns should be promptly addressed by seeking medical advice.

Consult a healthcare provider to understand the unique benefits of Endjerix-V compared to other Hepatitis B vaccines in the market. Individual responses to vaccines vary, emphasizing the importance of personalized medical guidance for optimal immunity.